Resources & Guides

Complete GLP-3 retatrutide dosage chart showing the Phase 2/3 clinical trial titration from 2mg to 12mg weekly. Includes what to expect at each dose, weight loss results by tier, side effects data, printable download, and free dosing calculator.

Complete tirzepatide dosage chart showing Mounjaro and Zepbound titration protocols week-by-week from 2.5mg to 15mg. Includes what to expect at each dose level, side effects by tier, printable download, and a free dosing calculator.

Retatrutide activates three hormone receptors at once. Here is what it actually does inside the body: appetite suppression, metabolic shifts, blood sugar regulation, and fat loss, all grounded in published Phase 2 data.

Retatrutide achieved 24.2% weight loss vs semaglutide's 14.9% in trials. Compare triple-agonist vs single-agonist mechanisms, approval status, clinical data, side effects, and find out which GLP-1 medication is right for you.

How much weight can you lose on retatrutide? This guide covers Phase 3 and Phase 2 clinical data, a month-by-month timeline, cross-drug comparison to tirzepatide and semaglutide, body composition breakdown, and what individual factors affect your results.

People search "GLP-3 retatrutide" after hearing the nickname online. There is no GLP-3 receptor. Retatrutide is a triple agonist hitting GLP-1, GIP, and glucagon. Here is where the name came from and what it means.

Ozempic is FDA-approved for type 2 diabetes, Wegovy for obesity, and retatrutide is investigational. The three sit in different regulatory and clinical spaces, so the comparison has to start with what they are actually approved for.

A side-by-side look at the single, dual, and triple agonists. Trial weight loss runs 14.9% (semaglutide), 20.9% (tirzepatide), and 24.2% (retatrutide), but the trials differ and only one pairing has a head-to-head study.

Comprehensive guide to understanding retatrutide dosing schedules, titration protocols, and dosage optimization for effective weight loss results.

Complete Zepbound (tirzepatide) dosage chart for weight management. Covers the full 2.5 mg to 15 mg titration schedule, SURMOUNT-1 weight loss by dose, KwikPen guide, missed-dose rules, and a Zepbound vs Wegovy comparison.

Retatrutide achieved 24.2% weight loss vs tirzepatide's 20.9%. Compare mechanisms, trial results, side effects, and find out which medication might work better for you.

Retatrutide results from clinical trials show 24.2% weight loss at 48 weeks with the 12mg dose. Detailed breakdown of trial data, timeline of results, body composition changes, and realistic expectations.

"GLP-3" is informal shorthand for triple-agonist drugs like retatrutide. This chart maps GLP-1 mono, GIP/GLP-1 dual, and triple agonists side by side on mechanism, FDA status, and trial weight loss.

Retatrutide is an investigational triple-agonist medication that activates GLP-1, GIP, and glucagon receptors. Phase 2 trials showed 24.2% weight loss, the highest ever recorded for a GLP-1 class drug. Learn everything about this breakthrough medication.

A dose-by-dose breakdown of retatrutide phase 3 weight loss results from the TRIUMPH program: TRIUMPH-1 (28.3% at 80 weeks), the 104-week extension (30.3%), TRIUMPH-4 (28.7%), safety data, and what investigational status means for access.

Complete guide to tirzepatide weight loss: SURMOUNT trial results showed 20.9% average weight loss at 72 weeks on 15mg dose. How it works, what to expect, timeline, dosing, comparison with Ozempic/Wegovy, and managing side effects.

There is no single semaglutide muscle loss figure. Four Tier 1 studies measured different populations, doses, and tissues, and the widely repeated percentages are back-calculations rather than stated trial results.

Most semaglutide Reddit roundups just repeat what the community believes. This one checks each recurring claim against the FDA label and the peer-reviewed literature, then labels it corroborated, contradicted, or anecdote only.

Tirzepatide does not selectively break down muscle. In the SURMOUNT-1 DXA substudy the fat-to-lean split of weight lost matched the placebo arm, the most defensible finding in tirzepatide's body composition literature.

A synthesis of what tirzepatide Reddit communities actually report in aggregate: weight-loss patterns, the side effects that come up most, the compounded-versus-brand debate, and where community talking points line up with the clinical evidence.

Ozempic face is the colloquial name for the gaunt, hollowed look that some people notice during rapid semaglutide weight loss. This guide covers the mechanism, who notices it most, whether it reverses, and the lifestyle steps that may soften it.

Retatrutide does not prevent lean mass loss, but the proportion lost is similar to other obesity treatments. Here is what the DEXA data shows, why the glucagon receptor is only a hypothesis, and what actually protects muscle.

Semaglutide-associated hair shedding is real, and unlike tirzepatide, alopecia is a labeled adverse event in the Wegovy prescribing information. This guide covers mechanism, dose-stratified risk, and the 6-9 month recovery timeline.

The Zepbound KwikPen list price is $1,086.37 a month without insurance. The LillyDirect Self Pay Journey Program (launched February 2026) brings cash-pay vials down to $299 for 2.5mg, $399 for 5mg, and a flat $449 for every dose from 7.5mg to 15mg. This guide covers Zepbound pricing only, with no Mounjaro overlap.

Tirzepatide-associated hair shedding is real but almost always temporary telogen effluvium triggered by rapid weight loss. This guide covers mechanism, risk factors, prevention, and the 6-12 month recovery timeline.

Mounjaro and Zepbound contain identical tirzepatide (LY3298176). The differences are indication, device, and insurance: not the molecule. Full comparison with cost data and decision framework.

Zepbound and Ozempic are approved for different conditions. Zepbound targets weight management; Ozempic targets type 2 diabetes. Compare tirzepatide vs semaglutide across mechanisms, trial results, dosing, and cost.

Mounjaro (tirzepatide) outperformed Ozempic (semaglutide) on both HbA1c reduction and weight loss in the SURPASS-2 trial. Ozempic holds the cardiovascular edge. Full comparison inside.

Zepbound contains tirzepatide, a dual agonist that activates both GLP-1 and GIP receptors simultaneously. Here is exactly what happens in your body, what SURMOUNT-1 showed at 72 weeks, and why the 5-day half-life matters for your dose schedule.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved as Mounjaro (type 2 diabetes) and Zepbound (weight loss, sleep apnea). Clinical trials show up to 20.9% weight loss. This guide explains the science clearly.

How much weight can you lose on semaglutide? STEP 1 trial data shows 14.9% mean body weight loss at 68 weeks, with 86.4% of participants losing at least 5%. This guide breaks down the clinical evidence, month-by-month timeline, real-world results, and what factors determine your outcome.

Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes and obesity. It's the active ingredient in Ozempic, Rybelsus, and Wegovy. This guide explains what it is, how it works, what the clinical trials show, and who qualifies for treatment.

Tirzepatide activates two hormone receptors — GLP-1 and GIP — producing greater fat loss than GLP-1-only drugs. Here's what each receptor does, why the mechanism isn't fully understood, and what the clinical trials show.

Retatrutide is the first triple agonist that activates GIP, GLP-1, and glucagon receptors at once. How each receptor contributes to weight loss, why it outperforms single and dual agonists, and what the clinical data shows.

Tirzepatide achieved 20.9% weight loss vs semaglutide's 14.9% in clinical trials. The SURPASS-2 head-to-head trial showed tirzepatide superior on both A1C and weight. Compare mechanisms, side effects, dosing, costs, and which GLP-1 medication fits your situation.

Both Ozempic and Wegovy contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes (max 1.0 mg) while Wegovy targets obesity (2.4 mg recommended maintenance, 7.2 mg maximum). Explore the differences.

Complete semaglutide dosage chart showing Ozempic (1.0 mg max) and Wegovy (2.4 mg maintenance, 7.2 mg max) titration protocols week-by-week. Includes what to expect at each dose level, side effects data, printable download, and a free dosing calculator.